Abstracts tagged "adalimumab and ankylosing spondylitis (AS)"

Abstract Number: 2622 • 2018 ACR/ARHP Annual Meeting
Regional and Temporal Variation in the Baseline Profile of Ankylosing Spondylitis Patients Initiating Adalimumab Following Failure of Non-Biologic Treatment in Canadian Routine Care
Louis Bessette^1,2, Majed Khraishi³, Viktoria Pavlova⁴, Brandusa Florica^5,6 and Valencia P. Remple^7,8, ¹Centre Hospitalier de l'Université Laval, Quebec, QC, Canada, ²Rheumatology, Laval University, Quebec, QC, Canada, ³Memorial University of Newfoundland, St. John's, NF, Canada, ⁴McMaster University, Hamilton, ON, Canada, ⁵Trillium Health Partners, Mississauga, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada, ⁸AbbVie Corporation, Montreal, QC, Canada
Background/Purpose: Treatment selection in Canadian routine clinical care is based on the judgment of the treating physician but is also affected by treatment guidelines and…
Abstract Number: 2847 • 2015 ACR/ARHP Annual Meeting
Predictors of Therapeutic Response in Ankylosing Spondylitis Patients Initiating Therapy with Adalimumab in a German Non-Interventional Study
Michaela Koehm^1,2, Frank Behrens^1,3, Eva C. Scharbatke⁴, Marc Schmalzing⁵, Holger Gnann⁶, Gerd Greger⁷, Bianca Wittig⁸, Hans Peter Tony⁹ and Harald Burkhardt^3,10, ¹Clinical Research, Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt/Main, Germany, ²Rheumatology, Goethe-University Frankfurt, Frankfurt/Main, Germany, ³Rheumatology, Goethe-University Frankfurt, Frankfurt, Germany, ⁴Rheumatology/Immunology, University of Würzburg, Würzburg, Germany, ⁵Rheumatology/Immunology, University Würzburg, Würzburg, Germany, ⁶Abteilung Biostatistik, GKM Gesellschaft für Therapieforschung mbH, München, Germany, ⁷AbbVie Deutschland GmbH & Co.KG, Wiesbaden, Germany, ⁸Abbott GmbH & Co KG, Wiesbaden, Germany, ⁹Rheumatology / Clinical Immunology, University Hospital Würzburg, Würzburg, Germany, ¹⁰Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt/Main, Germany
Background/Purpose: Ankylosing spondylitis (AS) is associated with a significant burden of illness and has limited treatment options. The identification of predictors of response to anti-tumor necrosis…
Abstract Number: 1509 • 2013 ACR/ARHP Annual Meeting
Immunogenicity, Adalimumab Levels and Clinical Response In Ankylosing Spondylitis Patients During 24 Weeks Of Follow-Up
Eva L. Kneepkens¹, James C. Wei², Michael T. Nurmohamed^3,4, Kai-Jieh Yeo⁵, CY Chen⁶, Irene E. van der Horst-Bruinsma^1,7, Desiree van der Kleij⁸, Theo Rispens⁹, Gertjan Wolbink^3,9 and Charlotte L. M. Krieckaert³, ¹Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²Allergy/Immunology/Rheumatolog, Chung Shan Med Univ Hospital, Taichung, Taiwan, ³Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁴Rheumatology, VU University medical centre, Amsterdam, Netherlands, ⁵Division of Allergy, Immunology and Rheumatology, Chung Shan Med Univ Hospital, Taichung, Taiwan, ⁶Chung Shan Med Univ Hospital, Taichung, Taiwan, ⁷Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁸Sanquin Diagnostic Services, Amsterdam, Netherlands, ⁹Sanquin Research, Amsterdam, Netherlands
Background/Purpose: Immunogenicity influences adalimumab levels and therefore clinical response in patients with rheumatic diseases. Objectives: To study the relation between clinical response, adalimumab levels and…